1668: Side Effects of Transrectal High Intensity Focused Ultrasound (HIFU) in the Local Treatment of Prostate Cancer in 8 Years

Chaussy, C.; Thueroff, S.

doi:10.1016/s0022-5347(18)35790-2

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it was decided for this review to focus on HIFU as primary therapy for prostate cancer. Considering this, 25 articles/ abstracts evaluating HIFU with the Ablatherm [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][35][36][37][38][39][40][41] and five with the Sonablate device were selected [23][24][25][26][27].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

Rébillard¹,

Soulié²,

Chartier‐Kastler

et al. 2008

BJU International

103

View full text Add to dashboard Cite

antigen (PSA) level of ≤ 28 ng/mL and a prostate volume of ≤ 40 mL. Negative biopsy rates with the Ablatherm TM device (EDAP TMS S.A., Vaulx-en-Velin, France) were 64-93%, and a PSA nadir of ≤ 0.5 ng/mL was achieved in 55-84% of patients. The 5-year actuarial disease-free survival rates were 60-70%. The most common complications were stress urinary incontinence, urinary tract infection, urethral/bladder neck stenosis or strictures, and erectile dysfunction. For the Ablatherm device, the rate of complications has been significantly reduced over the years, due to technical improvements in the device and the use of transurethral resection of the prostate before HIFU. In conclusion, HIFU as primary therapy for prostate cancer is indicated in older patients ( ≥ 70 years) with T1-T2 N0M0 disease, a Gleason score of < 7, a PSA level of < 15 ng/mL and a prostate volume of < 40 mL. In these patients HIFU achieves short-term cancer control, as shown by a high percentage of negative biopsies and significantly reduced PSA levels. The median-term survival data also seem promising, but long-term follow-up studies are needed to further evaluate cancerspecific and overall survival rates before the indications for primary therapy can be expanded.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In all, 37 articles/abstracts of studies evaluating the efficacy and/or safety of HIFU in prostate cancer were selected [5–41]. Data on HIFU as salvage therapy after RT were limited; only two fully published papers and five abstracts were identified [28–34].…”

Section: Resultsmentioning

confidence: 99%

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

Rébillard¹,

Soulié²,

Chartier‐Kastler

et al. 2008

BJU International

103

View full text Add to dashboard Cite

show abstract

“…Consequently, these patients need a therapeutic approach for their prostate cancer. We offered these patients HIFU as a local therapy and analyzed efficacy and side effects since 2000 [16].…”

Section: Incidental Prostate Cancermentioning

confidence: 99%

Robotic High-intensity Focused Ultrasound for Prostate Cancer: What Have We Learned in 15 Years of Clinical Use?

Chaussy

Thüroff

2011

Curr Urol Rep

View full text Add to dashboard Cite

High-intensity focused ultrasound (HIFU) is an emerging, noninvasive, local treatment of prostate cancer with 15 years of clinical experience, during which about 30,000 HIFU treatments have been performed worldwide. In this paper, we review relevant publications regarding the means by which new and old prostate cancer technologies are evaluated, the outcomes of HIFU by Ablatherm (EDAP TMS, Lyon, France), and the evolution currently underway regarding how prostate cancer is diagnosed and treated. We show the potential of HIFU to be used as local therapy for men with any stage of prostate cancer and how this additional therapeutic option can fit within the future armamentarium of a sequential multimodal therapy concept.

show abstract

1668: Side Effects of Transrectal High Intensity Focused Ultrasound (HIFU) in the Local Treatment of Prostate Cancer in 8 Years

Cited by 2 publications

References 0 publications

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

Robotic High-intensity Focused Ultrasound for Prostate Cancer: What Have We Learned in 15 Years of Clinical Use?

Contact Info

Product

Resources

About